XYnapse Therapeutics

XYnapse Therapeutics is a UK-based biotechnology company focused on developing transformative therapies for neurological disorders by targeting synaptic dysfunction. Spun out from the University of Oxford, the company leverages deep expertise in basal ganglia circuitry to address the root causes of conditions like Parkinson's disease. Their approach involves identifying and modulating specific synaptic pathways to restore normal brain function and connectivity. XYnapse is currently in the pre-clinical stage, advancing a pipeline of novel therapeutic candidates designed to provide disease-modifying benefits. The company is backed by leading life science investors and maintains strong ties to academic research centers.